VIP方案对EP、CE方案化疗失败肺癌病人的补救治疗39例近期疗效分析

Response Rate of Ifosfamide Plus Cisplatin and Etopside for Previously Treated Recurrent Small Cell Lung Cancer

摘要: 目的：探讨CP、CE方案化疗失败肺癌病人的补救治疗。方法：本文采用由异环磷酰胺、顺铂、鬼臼已叉甙组成的VIP方案治疗了39例接受EP、CE方案化疗后无效或复发的小细胞肺癌患者，平均化疗31周期。结果：完全缓解2例，部分缓解18例，总有效率51.3%。进一步分析表明无效病例的有效率明显高于复发病例，而进展率则明显低于复发病例。主要不良反应为骨髓抑制和胃肠道反应，结论：VIP方案具有较好的耐受性和安全性，在小细胞肺癌的补救治疗中具有一定的应用价值。

Abstract: This study was undertaken to determine the activity and toxicity of ifosfamide plus cisplatin and etopodide regimens (VIP) for previously treated recurrent small cell lung cancer.39 patients were assessable for response and toxicity.Main combination chemotherapy regimens,the patients had received previously were PE and CE.In this study,these patients received 2 3 courses of VIP.22 of 39 patients had an objective response,including 2 CR and 20 PR.Compared with PE、CE regimens,the main toxicity of VIP was myelosuppressioin and mild gastrointestinal reaction.We think that ifosfamide plus cisplatin and etopodide regiments (VIP) are an active regimen in the treatment of recurrent SCLC.But hematological toxicity was severe in these pretreated patients.